- feeds
- popular
- recent
- reader
- about
- story
- technologies
- what is rss
- connect
- dmca
- contact
- Feed Preview Alzheimers Treatment Coverage - MedCity News
A look at life science innovation brought on by physician-biopharm tech hybrids
In this series, Dialogues+ is taking a look at innovation brought about through collaborations between physicians and biopharmaceutical/medical technology companies. Today, we look to potential f...
J&J takes an early interest in biotech startup Alector’s approach to Alzheimer’s treatment
In another move to potentially beef up its Alzheimer’s pipeline, Johnson & Johnson has struck a drug development deal with one of the companies located at its innovation lab in San Francisco. J...
In Case You Missed It: Top 10 stories from January on MedCity News
Take a look at the most read stories on MedCity News in January. You may have missed news on startups, medical innovations and new healthcare mobile apps. The post In Case You Missed It: Top 10...
https://medcitynews.com/2014/02/top-10-stories-may-missed-medcity-news-january/
Clever Facebook campaign uses Photoshop + fake events to create Alzheimer’s experience
It was a month-long campaign to give average people a glimpse into what it’s like to have Alheimer’s disease — if only for a moment. The post Clever Facebook campaign uses Photoshop + fak...
In gamification milestone, Pfizer will assess video game in clinical trial for Alzheimer’s disease
In a move that could have a significant impact on how pharmaceutical companies view gamification, Pfizer (NYSE: PFE) has agreed to test the use of a mobile video game from Akili Interactive Labs ...
One healthcare market that’s not growing quickly: Alzheimer’s disease drugs
3D printing in medicine is “skyrocketing.” Diabetes drugs comprise a huge market already and are poised for “strong growth” over the next 10 years. But a new market report is the latest i...
Janssen turns to Evotec for help discovering new targets and drugs for Alzheimer’s disease
Despite a major setback last summer when its promising drug bapineuzumab failed in late-stage clinical trials, Janssen Pharmaceuticals is looking to beef up its Alzheimer’s disease drug pipelin...
3 neat ways to participate in crowdsourced cancer and Alzheimer’s disease research
Thanks to technology and the changing culture of medicine, those of us who don’t have thousands of dollars to donate to medical research have easier ways to contribute. Instead of money, we can...
https://medcitynews.com/2013/11/3-ways-participate-crowdsourced-disease-research/
Startup Alzheon’s proposal for Alzheimer’s drug success adds new science to old, failed trials
From a commercial perspective, the last few decades of Alzheimer’s drug development have largely been a wash of promising disease-altering drugs failing to demonstrate efficacy in late-stage tr...
Close look at 23andMe founder and what genetic testing means for adoptive parents
What began as an assignment to investigate and profile 23andMe Founder and CEO Anne Wojcicki took a personal turn for one adoptive parent and Fast Company contributor. In this article, a writer u...
Obesity: A Risk Factor for Alzheimer’s
This post is part of ongoing coverage of Cleveland Clinic’s 2013 Medical Innovation Summit: Finding Balance through Innovation. Obesity, Diabetes & the Metabolic Crisis. Much of the current res...
https://medcitynews.com/2013/10/obesity-risk-factor-alzheimers/
Want to solve your men’s health issue? Grow a mustache, join the Movember movement
Doctor Mike Evans’ Youtube Channel is one of my favorites. Watching “23 1/2 hours” changed my perspective on how I should be treating my body. Now, he and Movember CEO Adam Garone (TED Talk...
https://medcitynews.com/2013/10/want-solve-mens-health-issue-join-movember-movement/
NeuroTrack’s computer test for Alzheimer’s wins over Founders Fund, Social+Capital Partnership
What if a simple computer test administered in a doctor’s office could foretell which seniors would develop Alzheimer’s disease down the road? Startup NeuroTrack is working toward that, and n...
Neuro drug developer iPierian nets $30M, spins off new company for rare disease R&D program
Rather than leveraging stem cells for therapeutic use, iPierian Inc. has been using them to create disease models with which is can screen and develop new drugs. Now, with $30 million it’s just...
Navidea’s Alzheimer’s imaging agent moves into Phase 3 with Siemens deal, SBIR grant
Navidea Biopharmaceuticals (NYSE:NAVB) is getting some financial support from the NIH for its Alzheimer’s diagnostic technology as it advances into Phase 3 development. The National Institute o...
Foundations team up to fund translational research on mitochondrial diseases, Alzheimer’s
Two foundations are pairing up to fund work toward new treatments for a group of diseases caused by mitochondrial dysfunction. The Alzheimer’s Drug Discovery Foundation and Foundation for Mitoc...
Pharma company developing Alzheimer’s pill that targets link between blood sugar and brain health
A handful of high-profile Alzheimer’s disease drugs have failed in late-stage clinical trials in the last year — at least two of them based on the hypothesis that buildup of amyloid plaques i...
Learn from a pro: Strategies to interest angels and VCs in a medical device startup
Paul Hartung, CEO of Cognoptix, Inc., a startup that has created a drug-device that could diagnose Alzheimer’s earlier in patients, is also the first person to have a syndicated angel deal in t...
One to watch: Medical device company says eye test can diagnose Alzheimer’s
Cognoptix, Inc. claims to have created a working, in-office, non-invasive eye-scan that detects Alzheimer’s earlier in patients. The SAPPHIRE II tracks a beta amyloid (“Ab”) signature in th...
MindReader, Matched Flicker and 8 more cool startups we met at the healthcare innovation summit
In addition to all the smart, insightful speakers talking about innovation in healthcare and all the entrepreneurs in the startup showcase at CONVERGE last week, there were more than 50 other sta...
AARP reality check: Members tell healthcare startups which ideas are on time
We invited 50 AARP members from the Philadelphia chapter to CONVERGE. They talked with the entrepreneurs in the Pfizer Startup Showcase. These consumers were our reality check on innovation. A fe...
Alzheimer’s drug developers get their own version of Match.com for CROs
Big pharma’s move to outsource much of its research and development needs to contract research organizations have helped create a thriving CRO industry. The Alzheimer’s Drug Discovery Foundat...
J&J and Atlas Venture back launch of drug developer using epigenetics to treat Alzheimer’s disease
Johnson & Johnson (NYSE: JNJ) kicked off the launch of its Boston innovation center with news that it is backing a new drug developer targeting Alzheimer’s disease and other neurological disor...
After a restructure and an axed Merck deal, Acumen gains $20M for novel Alzheimer’s drug
It’s been 17 years in the making, but Acumen Pharmaceuticals hasn’t given up hope for its approach to a disease-modifying drug for Alzheimer’s disease. After restructuring to become a virtu...
Repurposed cancer drug to enter Phase I trials for Alzheimer’s disease this year
In the world of Alzheimer’s disease drugs, the past year has been marked by disappointing Phase 3 clinical trial results for a handful of much-anticipated antibody drugs. But the failure of tho...
Potential disease-altering drug for Alzheimer’s draws $6.4 million, with IND planned for 2014
A preclinical drug aimed at preventing misfolded proteins from getting tangled in the brain and potentially causing neurodegenerative disease has drawn another $6.4 million from investors. The la...
Three East Coast startups move to final round in health division at SxSW accelerator
Three West Coast investors picked three East Coast healthcare startups to move on to the final round of the SxSW health accelerator in Austin on Monday. NeuroTrack, Docphin and Careport Health be...
Weight loss simulator, hand-held counterfeit drug detector among HHS’ best innovations
In an effort to showcase that government entities are doing what they can to encourage innovation too, the U.S. Department of Health and Human Services (HHS) is inviting the public to review and ...
Global market for neuromodulation devices to grow to $6.8 billion by 2017
A new market report from MarketsandMarkets, a Dallas-based market research firm, is projecting that the global market for neuromodulation devices is set to grow to $6.8 billion by 2017. Another r...
America should be following the French to get better care for Alzheimer’s patients
Looking for a way to send ObamaCare foes into a tizzy? Try suggesting emulating the French system. In any way. Yet if we believe in learning from best practices, we should start doing what the Fr...